Why grade a class of compounds instead of each peptide?

Because the evidence situation is identical across the gray-market class: early hormone-level data, no outcome trials, no approval. If a member of the class ever earns its own record, it will get its own entry.

What actually raises growth hormone with evidence behind it?

Hard training and deep sleep — unglamorous, free, and documented. Start at the progressive overload and sleep regularity entries; that is not a deflection, it is the evidence-ranked answer.

STAXMAXXX INDEX / PERFORM / Clinical

GH Secretagogues (Ipamorelin / CJC-1295 Class)

Sold everywhere, proven almost nowhere.

STAXXX evidence grade · GH Secretagogues (Ipamorelin / CJC-1295 Class)

INSUFFICIENT

The human evidence is not there. Whatever you have heard, it has not been shown.

STRONG
MODERATE
EMERGING
INSUFFICIENT

Regulatory status: Unapproved / investigational
Sources on file: 2 total · 0 human · 1 pending
Rubric score: 0.13 weighted

Computed by the published STAXXX rubric · index-rubric.2026-08-15.1

WHAT IT IS

A family of peptides designed to stimulate the body's own growth-hormone release — ipamorelin and CJC-1295 are the names that circulate. None of the compounds in this gray-market class is an approved medicine, and the human evidence behind them stops at early pharmacology studies from programs that were shelved.

HOW IT WORKS

These peptides act on the pituitary's growth-hormone-releasing pathways, producing measurable short-term rises in growth-hormone pulses in early human pharmacology work. What was never demonstrated is the part being sold: that those pulses translate into meaningful muscle, fat-loss, or recovery outcomes in healthy adults, at acceptable risk, over time.

WHERE THE EVIDENCE STANDS

Hormone-level changes were documented in small early-phase studies; outcome benefits never were. Development programs were discontinued rather than completed, which is the pharmaceutical industry's own verdict on the risk-to-benefit math. Anti-doping authorities prohibit the class. INSUFFICIENT, by the same rubric every other entry faces.

SOURCES

REFERENCEPreclinicalPending document
Early-phase pharmacology literature on growth hormone secretagogue peptides
Multiple journals; discontinued development programs
Hormone-level effects documented; clinical outcome benefits not established.
REFERENCERegulatory status
Prohibited List — S2 category, peptide hormones and releasing factors
World Anti-Doping Agency

1 of 2 documents are not confirmed yet. Pending means pending.

REGULATORY STATUS

Unapproved / investigationalNot approved for human use. One relative of this family, tesamorelin, is an approved prescription drug for a specific medical condition — a fact gray-market sellers borrow to imply the whole class is legitimate. It is not, and the products sold online are not tesamorelin.

WHO THIS IS FOR

People researching peptides who keep finding stores where studies should be
Athletes who need to know this class is prohibited in tested sport, full stop

WHAT PEOPLE GET WRONG

Raising growth hormone naturally must build muscle.: Raising a hormone number and improving body composition are different claims. The second was never demonstrated for this class — and hard training and adequate sleep already drive growth-hormone release, with actual outcome evidence attached.
One of these is FDA-approved, so the class is vetted.: Tesamorelin is approved, for a specific condition, under prescription, at pharmaceutical quality. The compounds sold online share neither the approval, the indication, nor the supply chain.

QUESTIONS

Why grade a class of compounds instead of each peptide?: Because the evidence situation is identical across the gray-market class: early hormone-level data, no outcome trials, no approval. If a member of the class ever earns its own record, it will get its own entry.
What actually raises growth hormone with evidence behind it?: Hard training and deep sleep — unglamorous, free, and documented. Start at the progressive overload and sleep regularity entries; that is not a deflection, it is the evidence-ranked answer.